Abstract
Background and Aims: Merkel cell carcinoma (MCC) is an aggressive malignancy for which systemic therapy is standard of care in advanced disease. We assessed our institution’s experience with neoadjuvant systemic therapy (NST) in patients (pts) with surgically resectable MCC. Methods: A retrospective review of MCC patients who underwent surgery within the Dept. of Surgical Oncology at our institution from 2017 to 2021 was performed. Pts who received NST were identified and clinical characteristics, treatments received, pathological response and recurrence were examined.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.